Pfizer Consumer Healthcare - Diflucan one

Published in the Commonwealth of Australia Gazette No. GN 43, 2 November 2005

THERAPEUTIC GOODS ACT 1989

I, CRAIG DAVIES, Head - Advertising and Export Section, Non-Prescription Medicines Branch, Therapeutic Goods Administration and delegate of the Secretary to the Department of Health and Ageing for the purposes of Section 42DF(1) of the Therapeutic Goods Act 1989 -

1. hereby revoke the approval granted in relation to the product listed in paragraph (b), as published in the Commonwealth of Australia Gazette No. GN 30, 28 July 2004; and
2. having taken into consideration the recent change to the indications included in the Australian Register of Therapeutic Goods for the product, give notice that the restricted representation described in paragraph (a) below, has been approved for use in advertisements directed to consumers, for the product listed in paragraph (b):
   1. Representations to the effect that advertisements to consumers for the goods described in paragraph (b) may refer to:
      "for treatment of vaginal candidiasis (thrush)"
   2. Diflucan One (fluconazole 150mg single dose) (AUST R 100956);
      sponsored by Pfizer Consumer Healthcare.

Dated this 19th day of October 2005

CRAIG DAVIES
Delegate of the Secretary to the Department of Health and Ageing